Opexa Therapeutics Inc. (NASDAQ:OPXA) shares rose 5.1% during trading on Friday . The company traded as high as $4.73 and last traded at $4.50, with a volume of 176,003 shares traded. The stock had previously closed at $4.28.

OPXA has been the topic of a number of research reports. Chardan Capital restated a “buy” rating and set a $6.00 price target on shares of Opexa Therapeutics in a research note on Sunday, July 3rd. Maxim Group restated a “buy” rating on shares of Opexa Therapeutics in a research note on Friday, June 10th.

The stock’s 50 day moving average is $3.76 and its 200 day moving average is $2.62. The company’s market cap is $30.58 million.

Opexa Therapeutics (NASDAQ:OPXA) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. During the same quarter in the previous year, the firm earned ($0.96) earnings per share. On average, equities analysts anticipate that Opexa Therapeutics Inc. will post ($0.99) EPS for the current year.

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.